Nanoparticle Physicochemical Properties Drive Uptake Pathways in Human Corneal Epithelial Cells

Study Background and Research Question

Topical ophthalmic drug delivery faces intrinsic challenges, primarily due to the eye's robust defense mechanisms—namely the tear film and corneal epithelium—which limit drug residence time and tissue penetration. Conventional formulation strategies, such as viscosity enhancers and penetration agents, often result in unwanted side effects like irritation and blurred vision, and still fail to achieve optimal bioavailability. Against this backdrop, the referenced study by Azadi and David (2024) investigates the critical question: How do the physicochemical characteristics of polymeric nanoparticles, specifically size and surface chemistry, influence their uptake by human corneal epithelial cells (HCECs)?

Key Innovation from the Reference Study

The core innovation lies in the systematic dissection of how nanoparticle design variables—size (100–250 nm) and surface modification (mucoadhesive vs. mucopenetrative polymers)—dictate uptake mechanisms in an in vitro human corneal model. By focusing on PLGA-based nanoparticles and integrating mucosal simulation, the researchers bridge mechanistic understanding with translational relevance for ocular drug delivery. Notably, the study identifies macropinocytosis and caveolae-mediated endocytosis as the dominant cellular uptake pathways for these nanoparticles, providing a blueprint for rational nanoparticle engineering.

Methods and Experimental Design Insights

The researchers synthesized poly(lactic-co-glycolic) acid (PLGA) nanoparticles using an emulsion-solvent evaporation technique. Surface modifications included mucoadhesive coatings (alginate and chitosan) and a mucopenetrative polyethylene glycol (PEG) shell. The nanoparticles were characterized as monodisperse (PDI < 0.2), spherical, and with tunable size (100–250 nm) and zeta potential (−25 to +15 mV). Cytotoxicity was assessed via MTT assays, showing 70–100% cell viability after 24 h exposure at concentrations up to 100 μg/mL. In vitro uptake studies employed a HCEC monolayer with a simulated mucosal solution to replicate the ocular surface environment. Uptake mechanisms were probed using pharmacological inhibitors targeting specific endocytosis pathways (macropinocytosis, caveolae-, and clathrin-mediated endocytosis, as well as phagocytosis), thereby enabling mechanistic attribution for internalization events.

Protocol Parameters

• Nanoparticle formulation: PLGA nanoparticles synthesized via emulsion-solvent evaporation; surface modification with alginate, chitosan, or PEG for mucoadhesive/mucopenetrative properties.
• Particle size and charge: 100–250 nm in diameter; zeta potential ranging from −25 to +15 mV.
• Cell model: Human corneal epithelial cell (HCEC) monolayer combined with simulated mucosal solution to mimic in vivo conditions.
• Cytotoxicity assessment: MTT assay after 24 h nanoparticle incubation at concentrations up to 100 μg/mL.
• Uptake pathway analysis: Use of endocytosis inhibitors to dissect contributions of macropinocytosis, caveolae-, and clathrin-mediated endocytosis.

Core Findings and Why They Matter

The study demonstrates that both the size and surface chemistry of PLGA nanoparticles significantly impact their cellular uptake by HCECs. In particular, 100 nm PLGA nanoparticles and PEG-PLGA-150 (mucopenetrative) nanoparticles achieved the highest uptake levels. Uptake was determined to be energy-dependent, primarily mediated via macropinocytosis and caveolae-mediated endocytosis, with a partial role for clathrin-mediated pathways; phagocytosis was negligible within the tested parameters. These mechanistic insights provide actionable guidance: optimizing nanoparticle size around 100–150 nm and leveraging surface PEGylation can enhance ocular penetration and drug bioavailability while minimizing cytotoxicity.

Importantly, the in vitro model—with its integration of a mucosal solution—captures critical aspects of the ocular surface barrier, improving the predictive power for in vivo translation. By elucidating dominant uptake pathways, the study lays the groundwork for next-generation nanocarriers that overcome the limitations of traditional ophthalmic formulations.

Comparison with Existing Internal Articles and Implications for Antifungal Research

While the referenced study focuses on ocular drug delivery, its mechanistic framework has direct relevance for antifungal nanomedicine, including the delivery of compounds such as Nystatin (Fungicidin). Internal resources, such as "Nystatin (Fungicidin) for Candida Research" and "Nystatin (Fungicidin): Mechanistic Mastery and Strategic…", have previously detailed the challenges of antifungal resistance in non-albicans Candida and the importance of delivery strategies in optimizing efficacy. For example, the internal literature highlights how liposomal Nystatin demonstrates protective effects against Aspergillus infection in animal models at doses as low as 2 mg/kg/day, and underscores the critical role of drug formulation in determining both antifungal potency and host tolerability. The present study adds to this knowledge by clarifying how nanoparticle-based carriers can be engineered to maximize epithelial uptake—a principle that is directly relevant for researchers seeking to improve topical or targeted antifungal therapies. For instance, optimizing the size and surface modification of Nystatin-loaded nanoparticles could enhance inhibition of Candida albicans adhesion or improve outcomes in vulvovaginal candidiasis treatment models, as discussed in internal reviews.

Limitations and Transferability

Although the in vitro HCEC model with mucosal simulation advances physiological relevance, it cannot fully recapitulate the complexity of the in vivo ocular environment, including dynamic tear film turnover, immune surveillance, and drug clearance mechanisms. Additionally, the study was limited to a single cell type and did not evaluate functional drug delivery outcomes (e.g., pharmacodynamic efficacy or tissue distribution in vivo). As such, while the mechanistic findings are robust, further preclinical validation is needed before direct translation to clinical applications or to broader domains such as antifungal therapy for ocular or mucosal infections.

Research Support Resources

For researchers interested in leveraging these findings in antifungal models, Nystatin (Fungicidin) (SKU B1993) from APExBIO is available as a polyene antifungal with established efficacy against a range of Candida species and mycoplasma. Its mechanism—binding to ergosterol and disrupting fungal membrane integrity—complements nanoparticle delivery strategies designed to improve tissue penetration and retention. Practical guidance on integrating Nystatin into advanced in vitro or animal model workflows can be found in internal articles such as "Mechanistic Mastery and Strategic…". Researchers are encouraged to consider physicochemical compatibility, as well as established preparation and storage protocols, when designing nanoparticle-based antifungal studies.